By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Quest Diagnostics today said that it has completed the acquisition of Celera for around $671 million.

The Madison, NJ-based lab testing firm said that it completed the deal through a short-form merger after its tender offer expired last week. Each share of Celera common stock was converted into the right to receive the same $8 in cash, without interest and less any withholding of taxes, that was paid in the tender offer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.